IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0800399
(2001-03-05)
|
발명자
/ 주소 |
- Li, Jason
- Zhu, Steven Guoxin
|
출원인 / 주소 |
- Oplink Communications, Inc.
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
1 |
초록
▼
This invention discloses a method for detecting a leak from a sealed optical device. The method includes steps of: A) injecting a target gas with no performance interference to the sealed optical device for leak detection followed by sealing the sealed optical device. B) placing the sealed device in
This invention discloses a method for detecting a leak from a sealed optical device. The method includes steps of: A) injecting a target gas with no performance interference to the sealed optical device for leak detection followed by sealing the sealed optical device. B) placing the sealed device in a leak testing chamber and measuring a background level of the target gas in the leak testing chamber. C) heating the sealed device to a gas-expelling temperature for expelling the target gas from the leak in the sealed optical device. And, D) detecting the target gas in a one-part-per million (PPM) range in the leak-detecting chamber for an comparing with the background level of the target gas for determining the leak in the sealed optical device.
대표청구항
▼
This invention discloses a method for detecting a leak from a sealed optical device. The method includes steps of: A) injecting a target gas with no performance interference to the sealed optical device for leak detection followed by sealing the sealed optical device. B) placing the sealed device in
This invention discloses a method for detecting a leak from a sealed optical device. The method includes steps of: A) injecting a target gas with no performance interference to the sealed optical device for leak detection followed by sealing the sealed optical device. B) placing the sealed device in a leak testing chamber and measuring a background level of the target gas in the leak testing chamber. C) heating the sealed device to a gas-expelling temperature for expelling the target gas from the leak in the sealed optical device. And, D) detecting the target gas in a one-part-per million (PPM) range in the leak-detecting chamber for an comparing with the background level of the target gas for determining the leak in the sealed optical device. taining an active agent of topiramate, wherein the core particles have an initial particle size between about 0.100 mm and 2.5 mm; and (b) a taste mask coating, wherein the taste mask coating comprises between about 7% by weight and about 15% by weight of the pharmaceutical composition and wherein the coated particles of the pharmaceutical composition have a final particle size of about 0.100 mm to about 2.5 mm. 2. The method of claim 1, wherein the core particles comprise the active agent of topiramate and at least one excipient. 3. The method of claim 2, wherein the core particles comprise the active agent of topiramate, a binder and a diluent wherein the diluent is sugar spheres. 4. The method of claim 3, wherein the taste mask coating comprises between about 9% by weight and about 13% by weight of the pharmaceutical composition. 5. The method of claim 4, wherein the taste mask coating comprises about 11% by weight of the pharmaceutical composition. 6. The method of claim 5, wherein the core particles have an initial particle size between about 0.5 mm and 1.5 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.5 mm and 1.5 mm. 7. The method of claim 6, wherein the core particles have an initial particle size between about 0.710 mm and 1.18 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.850 mm and 1.18 mm. 8. The method of claim 7, wherein the binder is selected from povidone, HPMC, sodium alginate, panwar gum, acacia gum, gelatin, sugar, molasses, starch, pregelatinized starch, methylcellulose, ethylcellulose or carboxymethylecllulose; and the tase mask coating comprises a taste masking agent and a disintegrant, wherein the taste masking agent is selected from cellulose acetate, methylcellulose, ethylecellulose, a methacrylate or acrylate containing polymer or cellulose acetate butyrate; and the disintegrant is selected from povidone, cellulose, carboxycellulose, croscarmellose sodium, magnesium aluminum silicate, starch, sodium starch glycolate, pregelatinized starch, alginic acid or guar gum. 9. The method of claim 8, wherein the binder is povidone, the taste masking agent is cellulose acetate and the disintegrant is povidone. 10. The method of claim 9, wherein the coated particles of the pharmaceutical composition are encapsulated. 11. A method of treating diabetes in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising about 85 to about 93% by weight core beads, and about 7 to about 15% by weight of a coating; wherein the core beads comprise about 18 to about 21% by weight of topiramate, about 8 to about 11% by weight of povidone, and about 58 to about 61% by weight of sugar spheres; and the coating comprises about 6 to about 9% by weight of cellulose acetate, and about 2 to about 5% by weight of povidone. 12. The method of claim 11, wherein the pharmaceutical composition comprises about 89% by weight of core beads and about 11% by weight coating, wherein the core beads comprise about 19.8% by weight topiramate, about 9.9% by weight povidone, and about 59.3% by weight sugar spheres; and the coating comprises about 7.2% by weight cellulose acetate and about 3.8% by weight povidone. a patient; b) quantitatively measuring the pepsinogen-I from said serum sample using an immunoassay and comparing the value obtained to a cut-off value for pepsinogen-I selected from a range of approximately 20-30 μg/l, which overlaps the lower end of the reference range of approximately 25-120 μg/l; and c) quantitatively measuring the gastrin-17 concentration from said serum sample by immunoassay and comparing the values obtained to a reference range of approximately 2-25 pmol/l for gastrin-17, whereby a pepsinogen-I concentration in said serum sample below the cut-off value in combination with a gastrin-17 above the upper reference limit is indicative of atrophy of the corpus area of the stomach. 2. A method for screening for atrophy of the mucosa of the whole stomach from blood serum, such atrophy correlating with increased risk of gastric cancer, which comprises: a) obtaining a serum sample from a patient, b) quantitatively measuring the pepsinogen-I from said serum sample using an immunoassay and comparing the value obtained to a cut-off value for pepsinogen-I selected from a range of approximately 20-30 μg/l, which overlaps the lower end of the reference range of approximately 25-120 μg/l; and c) quantitatively measuring the gastrin-17 concentration from said serum sample and comparing the value obtained to a reference range of 2-25 pmol/l for gastrin-17, whereby a pepsinogen-I concentration in said serum sample below the pepsinogen-1 cut-off value and a gastrin-17 concentration in said serum sample within the reference range for gastrin-17 is indicative of atrophy of the mucosa of the whole stomach. 3. The method according to claim 1 or 2, further comprising a protein stimulation test that measures serum gastrin-17 concentration after fasting and then after a protein rich standard meal. 4. The method according to claim 1 or 2, wherein said immunoassay is conducted with an enzyme labeled antibody and a chromogenic, fluorescent or luminescent substrate, and absorbance, fluorescence or luminescence is measured. 5. The method according to claim 1 or 2, wherein said pepsinogen-I immunoassay is performed using polyclonal or monoclonal antibodies which specifically bind to said pepsinogen-I. 6. The method according to claim 1 or 2, wherein said gastrin-17 immunoassay is performed using polyclonal or monoclonal antibodies which specifically bind to said gastrin-17. 7. The method according to claim 6, wherein a polyclonal antibody to gastrin-17 is obtained by immunizing an animal with the gastrin fragment 1-13, {Leu15}-gastrin-17 or using a gastrin-17 antigen isolated from the stomach of an animal. 8. The method according to claim 6, wherein said monoclonal antibodies are mouse monoclonal antibodies which specifically bind to {Leu15}-gastrin-17 antigen. 9. The method according to claim 1 or 2, further comprising an immunoassay to detect the presence of Helicobacter pylori antibodies. 10. A method for screening for atrophy of the antrum area of the stomach from blood serum such atrophy correlating with increased risk of gastric cancer, which comprises: a) obtaining a blood serum sample from a patient b) quantitatively measuring the pepsinogen-I concentrations using an immunoassay and comparing the value obtained to a cut-off value for pepsinogen-I selected from the range of approximately 20-30 μg/l, which overlaps the lower end of the reference range of approximately 25-120 g/l; and c) quantitatively measuring the gastrin-17 concentration from said serum sample by immunoassay and comparing it to a cut-off value for gastrin-17 selected from a range of approximately 0.1-2 pmol/l, which is below the reference range of approximately 2-25 pmol/l whereby a pepsinogen I concentration above said cut-off value in combination with a gastrin-17 concentration in said sample below said cut-off value is indicative of atrophy of the antrum area of the stomach. 11. The method according to claim 10
※ AI-Helper는 부적절한 답변을 할 수 있습니다.